Drugs / Pro-ocular™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04769648 | Apr 2021 → Aug 2023 | graft versus host disease | Glia, LLC | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04884217 Comparator | May → Oct 2021 | dry eye syndrome | PharmaDax Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pro-ocular | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04884217 ↗ |
| Route | Topical | “Pro-ocular™ is a topical gel applied dermally to forehead twice-daily” NCT04769648 ↗ |